Dr. Reddy's Laboratories rang the Closing Bell at the New York Stock Exchange (NYSE) on May 29, 2026, to celebrate 25 years of its listing. The company became the first pharmaceutical firm in Asia, outside Japan, to be listed on the NYSE in April 2001. This milestone highlights the company's long-standing presence in the global market and its commitment to governance and transparency.

The ceremony took place at the NYSE headquarters in New York City at 4.00 pm EDT (1.30 am IST on May 30). It was livestreamed on NYSE.com and the New York Stock Exchange YouTube channel. The event marks a significant achievement for the company, reinforcing its position as a trusted name in the U.S. market.

The senior management team, led by Chairman Satish Reddy, participated in the ceremony. Key attendees included Erez Israeli, Chief Executive Officer; M.V. Ramana, Chief Executive Officer-Global Generics; and M.V. Narasimham, Chief Financial Officer. Independent Directors Arun M. Kumar, Penny Wan, and Sridar Iyengar (former Independent Director) were also present.

Satish Reddy, Chairman, emphasized the significance of this milestone, stating it reaffirms the company's commitment to global governance and innovation. He noted that the vision of founder Dr. K. Anji Reddy to bring affordable medicines to patients worldwide continues to drive the company's operations.

Dr. Reddy's Laboratories is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, the company offers a portfolio of products and services, including APIs, generics, branded generics, biosimilars, and OTC medicines. Its major therapeutic areas include gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.

Dr. Reddy's Laboratories Ltd has informed the stock exchanges about the transfer of unclaimed dividends and underlying equity shares to the Investor Education and Protection Fund (IEPF). The company published a notice in this regard on May 27, 2026, in newspapers Business Standard and Nava Telangana. This transfer is being carried out pursuant to Section 124(6) of the Companies Act, 2013, and the rules thereunder.

The disclosure was submitted to the National Stock Exchange of India Ltd and BSE Limited. The notice serves to inform shareholders and ensure compliance with regulatory requirements regarding unclaimed corporate benefits.

Details of the Disclosure

The company provided specific details regarding the publication and the regulatory framework governing the transfer of funds.

The filing was signed by K Randhir Singh, Company Secretary, Compliance Officer & Head-CSR of Dr. Reddy's Laboratories Limited. The document was digitally signed on May 27, 2026.